NASDAQ:PDSB • US70465T1079
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for PDS BIOTECHNOLOGY CORP (PDSB).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-11-25 | B. Riley Securities | Maintains | Buy -> Buy |
| 2025-11-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-07-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-06-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-27 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-25 | B. Riley Securities | Maintains | Buy -> Buy |
| 2024-11-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-02 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-20 | Alliance Global Partners | Maintains | Buy -> Buy |
| 2024-08-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-12 | B. Riley Securities | Maintains | Buy -> Buy |
| 2024-06-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-09 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-05-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-28 | B. Riley Securities | Reiterate | Buy -> Buy |
| 2024-03-27 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-15 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2023-10-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A 2,709.34% | N/A 111.73% | N/A 211.73% | N/A 14.41% | ||||||||||||
| EBITDA YoY % growth | -26.45M | -39.41M -49.00% | -51.79M -31.41% | -30.92M 40.30% | -14.91M 51.78% | -14.88M 0.20% | -21.43M -44.02% | -41.62M -94.21% | -42.988M -3.29% | -36.261M 15.65% | -31.484M 13.18% | N/A -29.59% | N/A -20.00% | N/A -10.63% | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -26.5M | -39.51M -49.09% | -51.97M -31.54% | -31.09M 40.18% | -15.01M 51.72% | -14.9M 0.73% | -21.44M -43.89% | -41.67M -94.36% | -43.045M -3.30% | -36.321M 15.62% | -31.544M 13.15% | N/A -18.83% | N/A -14.29% | N/A -30.62% | N/A 179.84% | N/A 254.26% | N/A 230.42% | N/A 16.19% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | -27.00 85.25% | -33.60 -24.44% | N/A | N/A | -0.99 31.65% | -0.63 36.36% | -1.45 -130.16% | -1.39 4.14% | -1.03 25.90% | -0.76 26.54% | N/A 8.33% | N/A 0.98% | N/A 7.18% | N/A 172.00% | N/A 251.11% | N/A 394.94% | N/A 15.98% |
All data in USD
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in USD
9 analysts have analysed PDSB and the average price target is 7.65 USD. This implies a price increase of 1104.72% is expected in the next year compared to the current price of 0.635.
PDS BIOTECHNOLOGY CORP (PDSB) will report earnings on 2026-05-12.
The consensus rating for PDS BIOTECHNOLOGY CORP (PDSB) is 82.2222 / 100 . This indicates that analysts generally have a positive outlook on the stock.